QUEST DIAGNOSTICS INC
Quest Diagnostics (DGX) reported 2Q and six-month 2026 results and raised full-year revenue and earnings guidance, according to the company. The article cites DGX shares up 8.34% (1 month), 23.58% (90 days), and 37.26% (1 year). It notes a fair value estimate of $239.38 versus a $233.72 close and flags reimbursement cuts and higher wage and automation costs as risks.
Daimini Chokshi Quest Diagnostics recruits Merck executive director Daimini Chokshi to serve as VP, investor relations, based at the company’s headquarters in Secaucus. During almost two decades at Merck, Chokshi held positions including director, investor relations and director, U.S. oncology finance.
Quest Diagnostics (NYSE: DGX) and Hologic, Inc. reported a Health Trends study using deidentified molecular lab data from 1.5 million women tested at Quest from 2022-2024. BV was found in 38.7% of cases; 12.0% of BV-positive women also had at least one STI versus 3.8% of BV-negative. BV-positive status showed higher odds of chlamydia, gonorrhea, and trichomonas.
Over the past 7 days, alphai's AI scored 1 news story mentioning DGX (QUEST DIAGNOSTICS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DGX coverage spans earnings, financial news and technology.
In the last 30 days, DGX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($376K). The most active reporter was DELANEY MARK E, SVP & Chief Commercial Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance lift supports bullish near-term sentiment, but the article flags reimbursement cuts and cost pressure as key margin risks.
The article discloses a senior investor-relations leadership change at Quest, which can shift communications cadence but has no direct financial guidance or operational update.
The study is a clinical evidence update tied to Quest’s testing platform, but it is not a financial or regulatory catalyst.
Forecast lift plus margin support from automation/AI suggests near-term upside bias, with follow-through dependent on continued execution.
PT increase suggests improved forward assumptions (valuation and/or earnings outlook) but no new company-specific operational datapoint is provided in the text.
alphai scores every news story that mentions DGX with an AI model for sentiment and relevance, and aggregates insider trades from QUEST DIAGNOSTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Quest Diagnostics (DGX) reported 2Q and six-month 2026 results and raised full-year revenue and earnings guidance, according to the company. The article cites DGX shares up 8.34% (1 month), 23.58% (90 days), and 37.26% (1 year). It notes a fair value estimate of $239.38 versus a $233.72 close and flags reimbursement cuts and higher wage and automation costs as risks.
5 min readDaimini Chokshi Quest Diagnostics recruits Merck executive director Daimini Chokshi to serve as VP, investor relations, based at the company’s headquarters in Secaucus. During almost two decades at Merck, Chokshi held positions including director, investor relations and director, U.S. oncology finance.
2 min readQuest Diagnostics (NYSE: DGX) and Hologic, Inc. reported a Health Trends study using deidentified molecular lab data from 1.5 million women tested at Quest from 2022-2024. BV was found in 38.7% of cases; 12.0% of BV-positive women also had at least one STI versus 3.8% of BV-negative. BV-positive status showed higher odds of chlamydia, gonorrhea, and trichomonas.
3 min readQuest Diagnostics (NYSE: DGX) shares rose over 8% last week after the company raised its full-year outlook. In Q2, revenue increased 10% to $3 billion, with adjusted EPS up 19% to $3.12. Quest projects full-year revenue around $12 billion and adjusted EPS of $11.05 to $11.25, citing growth and margin gains from automation and AI.
4 min readMorgan Stanley raised its price target for Quest Diagnostics to $260 from $226 and kept an Overweight rating, according to the note cited by MT Newswires. The article also mentions Evercore ISI cutting its target to $240 from $225. Quest Diagnostics last closed at $227.90.
1 min readQuest Diagnostics (NYSE:DGX) reported Q2 CY2026 results. Revenue rose 10.2% year on year to $3.04 billion, exceeding Wall Street estimates by 2.3%. Non-GAAP adjusted EPS was $3.12, up from $2.62 and 10.5% above consensus. Analysts expect full-year revenue growth of 4.5% and EPS to rise from $10.64 to $11.17.
4 min readQuest Diagnostics (DGX) shares rose about 7.3% in pre-open trading after the company reported Q2 2026 adjusted EPS of $3.12 versus $2.82 expected, and revenue of $3.04B versus $2.97B. Quest lifted full-year guidance to $11.95B-$12.05B revenue and $11.05-$11.25 adjusted EPS. Jefferies raised its price target to $225 from $220.
3 min readQuest Diagnostics (DGX) reported Q2 results and raised its FY2026 guidance. It now expects GAAP earnings of $9.97 to $10.17 per share and adjusted earnings of $11.05 to $11.25, on revenue of $11.95B to $12.05B, versus prior ranges of $9.58 to $9.78, $10.63 to $10.83, and $11.78B to $11.90B. Shares were up 5.71% premarket.
2 min readQuest Diagnostics (DGX) reported second-quarter results and raised its FY26 outlook, including adjusted earnings. The company posted quarterly profit of $320 million, or $2.84 per share, and shares rose about 5.7% following the update, according to the report.
2 min readQuest Diagnostics (DGX) reported second-quarter results, with its bottom-line profit rising to $320 million, or $2.84 per share, versus the prior year. The company also increased its FY26 outlook for earnings and adjusted earnings, and shares were up about 5.7% following the release, according to the report.
2 min read
